- BioNTech and Australia’s State of Victoria will set up an mRNA analysis and innovation middle to strengthen translational analysis for progressive medicines from discovery to supply
- As half of the partnership, BioNTech is dedicated to constructing a BioNTainer® facility for end-to-end scientific scale manufacturing of mRNA-based merchandise and candidates in Melbourne
- BioNTech plans to additional develop its scientific growth capabilities in Australia and consider the testing of extra scientific most cancers product candidates, together with the autologous CAR-T cell remedy candidate BNT211, along with two Phase 2 candidates at the moment being examined in Australia
MELBOURNE, Australia, October 7, 2022 —BioNTech SE (Nasdaq: BNTX) right this moment introduced that it has agreed a Letter of Intent with the State of Victoria in Australia on a strategic partnership between the State and BioNTech to collaborate on the analysis and growth of potential mRNA-based vaccines and therapies. As half of the partnership, the events will set up a analysis and innovation middle in Melbourne to facilitate the transition of encouraging educational analysis into scientific growth. BioNTech plans to arrange a scientific scale end-to-end mRNA manufacturing facility primarily based on its BioNTainer answer in Melbourne with the purpose of supporting the design, manufacture and scientific testing of product candidates. Part of BioNTech’s international community, the ability is anticipated to draw curiosity from researchers domestically, regionally and globally.
“Science and innovation can only make a difference if it is applied outside of the laboratories and reaches people worldwide. This partnership is a major step forward to enable access to mRNA technology and promote collaborations in the Asia-Pacific region,” mentioned Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Australia provides excellent academic research, and we are looking forward to collaborating with world-class scientists and researchers to strengthen Australia’s mRNA ecosystem and to jointly develop potential novel treatments and vaccines for people worldwide.”
As half of this collaboration, the State of Victoria and BioNTech will set up a analysis and innovation middle, directed in partnership with the State, with the purpose to help Australia’s mRNA ecosystem by curating tasks and to find out their potential transition into preclinical and scientific growth, supported by BioNTech’s recommendation and know-how. The partnership can even embrace the analysis and growth of experimental therapies together with mRNA-based product candidates for indications with excessive unmet medical want, as an example in oncology. BioNTech will help the R&D efforts on a project-by-project foundation with the Company’s experience in mRNA analysis and scientific growth of potential new merchandise.
In addition to driving progressive translational analysis, BioNTech can even help native supply by growing and commissioning an end-to-end clinical-scale manufacturing facility for mRNA-based medicines and product candidates in Melbourne, Victoria. BioNTech has developed the BioNTainer, a cellular modular manufacturing unit requiring restricted house for operation, permitting for well timed and versatile native manufacturing of completely different mRNA-based constructs and merchandise throughout a range of indications, and expects to create tons of of jobs throughout building and operation in Melbourne.
“We at BioNTech are committed to global public health, and as we continue to expand internationally, we look forward to working jointly to drive the development of innovative medicines,” mentioned Dr. Sierk Poetting, COO of BioNTech. “Our BioNTainers are designed as turnkey manufacturing sites for mRNA-based medicines and product candidates. In Melbourne, our BioNTainers will allow for an end-to-end production including fill and finish for clinical-scale manufacturing of mRNA candidates, once approved.”
BioNTech intends to additional strengthen the scientific growth capabilities in Australia and consists of websites that purpose to speed up the event of its scientific stage oncology pipeline which at the moment encompasses a complete of 18 product candidates in 23 ongoing scientific trials. BioNTech is at the moment recruiting most cancers sufferers for 2 Phase 2 mRNA-based product candidates in Australia – BNT111 and BNT113 – and plans to additional develop its scientific growth, together with for the Company’s candidate BNT211, which mixes a CAR-T cell remedy method with an mRNA vaccine.
About BioNTech
Biopharmaceutical New Technologies is a subsequent technology immunotherapy firm pioneering novel therapies for most cancers and different critical ailments. The Company exploits a wide selection of computational discovery and therapeutic drug platforms for the speedy growth of novel biopharmaceuticals. Its broad portfolio of oncology product candidates consists of individualized and off-the-shelf mRNA-based therapies, progressive chimeric antigen receptor T cells, bispecific immune checkpoint modulators, focused most cancers antibodies and small molecules. Based on its deep experience in mRNA vaccine growth and in-house manufacturing capabilities, BioNTech and its collaborators are growing a number of mRNA vaccine candidates for a spread of infectious ailments alongside its various oncology pipeline. BioNTech has established a broad set of relationships with a number of international pharmaceutical collaborators, together with Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For extra data, please go to www.BioNTech.com.
BioNTech Forward-looking Statements
This assertion incorporates forward-looking statements throughout the which means of the Private Securities Litigation Reform Act of 1995. These forward-looking statements might embrace, however will not be restricted to, direct or oblique statements regarding: BioNTech’s potential collaboration between the State of Victoria in Australia and its main scientific establishments as regards to pandemic preparedness and the event of progressive medicines; the power of BioNTech to achieve an settlement with potential collaboration companions in Australia; the power of BioNTech to supply, ship and set up mRNA container manufacturing amenities in Australia, together with the power to satisfy all essential infrastructure, expertise and regulatory necessities; potential delays within the institution of the BioNTainers in Australia, as a result of unexpected occasions, together with, however not restricted to, international provide chain points; the event of high quality assurance capabilities to remotely help manufacturing websites in Australia; the scale-up of native know-how and coaching in Australia; the event of sustainable RNA vaccine capacities, manufacturing and provide options in Australia and the character, timing, and feasibility of these options; the potential security and efficacy of the product candidates; BioNTech’s means to develop and commercialize merchandise; and BioNTech’s anticipated market alternative and dimension for its product candidates, the speed and diploma of market acceptance of BioNTech’s investigational medicines, if authorised. Any forward-looking statements on this assertion are primarily based on BioNTech’s present expectations and beliefs of future occasions, and are topic to a quantity of dangers and uncertainties that would trigger precise outcomes to vary materially and adversely from these set forth in or implied by such forward-looking statements.
For a dialogue of these and different dangers and uncertainties, see BioNTech’s Quarterly Report as Form 6-Ok for the quarter ended June 30, 2022, filed with the SEC on August 8, 2022, which is on the market on the SEC’s web site at www.sec.gov. All data on this press launch is as of the date of the discharge, and BioNTech undertakes no obligation to replace this data until required by legislation.
CONTACTS
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
[email protected]
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
[email protected]